MedicalResearch.com Interview with:
Jonathan Strosberg MD
Moffitt Cancer Center, Tampa, FL
MedicalResearch.com: What is the background for this study?
Response: Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life. We assessed the impact of 177Lu-Dotatate treatment on time to deterioration in health-related quality of life in patients with advanced midgut neuroendocrine tumors in the NETTER-1 study.
MedicalResearch.com: What are the main findings?
Response: Our analysis demonstrates that 177Lu-Dotatate provides a statistically significant and clinically robust delay in time to deterioration of health-related quality of life (since randomization into the study) for patients with progressive midgut NETs compared with high-dose octreotide. This benefit is seen across multiple clinically relevant symptom categories, including diarrhea, fatigue, and pain. Patients also experience similar benefits in functional health-related quality of life categories, including those pertaining to basic and advanced activities of daily living. Perhaps most importantly, patients report significant and sustained maintenance in their overall health since their entrance into the study.
MedicalResearch.com: What should readers take away from your report?
Response: Health-related quality of life is a vitally important standard to assess when evaluating the overall benefit of new treatments. In patients with advanced NETs, maintenance of an acceptable health-related quality of life is particularly important, given the relatively long durations of treatment and overall survival.
This publication demonstrates that 177Lu-Dotatate treatment provided a significantly longer maintenance of key quality of life measures before patients in the study started experiencing deterioration.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: Given the impact of 177Lu-Dotatate treatment on progression free survival and health related quality of life in this patient population, it would be worthwhile to examine the effects of this therapy in other somatostatin receptor expressing tumors.
Consulting or Advisory Role: Novartis, Lexicon, Ipsen
Speakers’ Bureau: Ipsen, Lexicon
Research Funding: Novartis, Pharmacyclics
Travel, Accommodations, Expenses: Advanced Accelerator Applications
Jonathan Strosberg, Edward Wolin, Beth Chasen, Matthew Kulke, David Bushnell, Martyn Caplin, Richard P. Baum, Pamela Kunz, Timothy Hobday, Andrew Hendifar, Kjell Oberg, Maribel Lopera Sierra, Thomas Thevenet, Ines Margalet, Philippe Ruszniewski, Eric Krenning, and on behalf of the NETTER-1 Study Group
Journal of Clinical Oncology 0 0:0
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.